Advancing Neurology Testing with
Blood Biomarkers Revealing neurological insights with lab diagnostics
Neurologic conditions are a global challenge, affecting more than one third of the population. Between 1990 and 2021, there has been an 18% rise in disability, illness, and premature death, making these conditions a leading cause of health burdens worldwide¹. As the field of neurology continues to advance, the rising prevalence of neurological conditions underscores the importance of innovations in diagnosis, prognosis, and monitoring. The growing trend in neurology innovation highlights the need for cutting-edge solutions, particularly for diseases such as Alzheimer’s and multiple sclerosis, which require precise diagnostic solutions.
Through extensive research and development, Siemens Healthineers is driving this innovation by developing novel blood-based biomarker assays for both clinical use and neuroscience research across the different neurological conditions. Innovation in this space is key at Siemens Healthineers, particularly in conditions like multiple sclerosis, where our groundbreaking Neurofilament Light Chain assay can unlock profound neurological insights through something as simple as a blood test.